Mylan Inc. has launched lamivudine tablets, 100 mg, which is the generic version of GlaxoSmithKline’s Epivir-HBV. Mylan received final approval from the US Food and Drug Administration for its abbreviated new drug application for this product, which is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation.

Lamivudine tablets, 100 mg, had US sales of approximately $18.1 million for the 12 months ending September 30, 2014, according to IMS Health, and as reported by Mylan.

Source: Mylan